/

Charles River Laboratories International, Inc.

CRL US

CRL USCharles River Laboratories International, Inc.

United States Composite

228.62

USD

-1.45

(-0.63%)

9.22EPS Dil.

24.68P/E

11.74BMarket Cap

Charles River Laboratories International, Inc.

CRL

(United States Composite)

Recent

price

228.62

P/E

ratio

24.68

div

yld

- -

ROIC.AI

Legends:

Stock price

1.39

Beta (1.0 Market)

% total return 04/18

Stock

S&P500

YTD

25.87

- -

-19.81

- -

91.88

- -

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

19.97

17.92

18.12

22.48

23.58

24.41

27.83

29.32

35.76

39.12

47.26

53.79

59.01

70.39

78.25

80.61

-7.76

1.75

-5.38

2.16

2.03

2.15

2.72

3.21

3.29

2.60

4.72

5.17

7.35

7.77

9.57

9.27

1.23

2.22

2.02

3.07

3.35

3.52

4.16

5.20

5.56

4.96

6.28

6.99

7.67

10.58

5.80

7.13

- -

-5.14

-3.61

-10.18

-9.51

-7.62

-5.57

-2.91

0.24

3.51

6.11

0.88

5.74

12.58

19.44

28.14

36.77

9.07

10.81

6.54

4.84

6.42

7.35

4.32

0.98

-6.93

-2.33

-10.78

-11.52

-9.10

-23.40

-15.34

-5.85

1,343

1,172

1,133

1,143

1,130

1,166

1,298

1,363

1,681

1,858

2,266

2,621

2,924

3,540

3,976

4,129

18.63

14.48

11.28

15.91

14.68

12.99

13.69

15.14

14.13

15.52

14.62

13.40

14.80

16.66

16.37

14.95

127

131

162

198

235

266

304

314

-522

114

-337

110

103

127

149

155

123

226

252

364

391

486

475

- -

26.63

- -

12.92

21.29

23.79

26.84

22.20

29.98

57.71

19.33

16.45

18.30

17.03

20.93

17.36

-38.84

9.77

-29.70

9.59

8.61

8.82

9.76

10.95

9.20

6.64

9.99

9.61

12.46

11.04

12.23

11.49

317

346

293

209

143

306

285

247

227

363

340

311

361

241

347

554

541

457

670

703

527

642

741

846

1,208

1,114

1,637

1,966

2,085

2,917

3,097

3,066

1,199

1,374

689

527

603

665

704

766

854

1,064

1,338

1,666

2,144

2,592

3,024

3,659

- -

6.83

- -

11.91

10.27

8.75

9.16

10.27

8.86

5.58

10.12

8.70

8.79

9.89

8.81

7.94

- -

54.32

- -

76.43

44.21

32.44

24.59

20.24

14.84

9.32

17.30

14.79

16.84

13.06

12.29

12.13

- -

174.33

54.14

136.32

155.86

80.36

48.65

40.27

28.58

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

2,678

2,514

2,647

LT Finance Leases

402

390

419

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

10,779

10,053

12,136

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

1,505

1,444

1,609

Cash, Cash Equivalents & STI

200

157

277

Accounts Receivable, Net

591

592

578

Inventories

285

293

380

Total Current Liabilities

1,008

994

1,055

Payables & Accruals

406

379

397

ST Debt

- -

Deferred Revenue

335

320

242

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

13.66%

12.89%

3.85%

Net Income, GAAP

19.31%

17.08%

-2.26%

Free Cash Flow

11.00%

8.78%

23.73%

Total Cash Common Dividend

- -

Total Equity

18.83%

22.35%

21.00%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

825

915

896

905

3,540

2022

914

973

989

1,100

3,976

2023

1,029

1,060

1,027

1,013

4,129

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

1.23

1.76

2.05

2.73

7.77

2022

1.84

2.15

1.90

3.68

9.57

2023

2.02

1.89

1.70

3.65

9.27

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Company News

Yahoo
17 days ago
Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market Following Fundamentals?
Yahoo
17 days ago
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
Yahoo
22 days ago
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
Zacks
23 days ago
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
Yahoo
a month ago
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies
Yahoo
a month ago
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Zacks
a month ago
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
Yahoo
a month ago
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
Zacks
a month ago
Charles River (CRL) Extends Gene Therapy Offering With New Pact
Zacks
a month ago
Here's Why You Should Retain Charles River (CRL) Stock Now
Yahoo
a month ago
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
Yahoo
a month ago
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Yahoo
a month ago
Insider Sell: CSVP & Chief Accounting Officer Michael Knell Sells Shares of Charles River ...
Yahoo
a month ago
Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Yahoo
a month ago
The Top 3 Healthcare Stocks to Buy in March 2024

Company News

Yahoo
17 days ago
Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market Following Fundamentals?
Yahoo
17 days ago
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
Yahoo
22 days ago
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
Zacks
23 days ago
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
Yahoo
a month ago
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies
Yahoo
a month ago
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Zacks
a month ago
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
Yahoo
a month ago
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
Zacks
a month ago
Charles River (CRL) Extends Gene Therapy Offering With New Pact
Zacks
a month ago
Here's Why You Should Retain Charles River (CRL) Stock Now
Yahoo
a month ago
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
Yahoo
a month ago
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Yahoo
a month ago
Insider Sell: CSVP & Chief Accounting Officer Michael Knell Sells Shares of Charles River ...
Yahoo
a month ago
Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Yahoo
a month ago
The Top 3 Healthcare Stocks to Buy in March 2024

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

19.97

17.92

18.12

22.48

23.58

24.41

27.83

29.32

35.76

39.12

47.26

53.79

59.01

70.39

78.25

80.61

-7.76

1.75

-5.38

2.16

2.03

2.15

2.72

3.21

3.29

2.60

4.72

5.17

7.35

7.77

9.57

9.27

1.23

2.22

2.02

3.07

3.35

3.52

4.16

5.20

5.56

4.96

6.28

6.99

7.67

10.58

5.80

7.13

- -

-5.14

-3.61

-10.18

-9.51

-7.62

-5.57

-2.91

0.24

3.51

6.11

0.88

5.74

12.58

19.44

28.14

36.77

9.07

10.81

6.54

4.84

6.42

7.35

4.32

0.98

-6.93

-2.33

-10.78

-11.52

-9.10

-23.40

-15.34

-5.85

1,343

1,172

1,133

1,143

1,130

1,166

1,298

1,363

1,681

1,858

2,266

2,621

2,924

3,540

3,976

4,129

18.63

14.48

11.28

15.91

14.68

12.99

13.69

15.14

14.13

15.52

14.62

13.40

14.80

16.66

16.37

14.95

127

131

162

198

235

266

304

314

-522

114

-337

110

103

127

149

155

123

226

252

364

391

486

475

- -

26.63

- -

12.92

21.29

23.79

26.84

22.20

29.98

57.71

19.33

16.45

18.30

17.03

20.93

17.36

-38.84

9.77

-29.70

9.59

8.61

8.82

9.76

10.95

9.20

6.64

9.99

9.61

12.46

11.04

12.23

11.49

317

346

293

209

143

306

285

247

227

363

340

311

361

241

347

554

541

457

670

703

527

642

741

846

1,208

1,114

1,637

1,966

2,085

2,917

3,097

3,066

1,199

1,374

689

527

603

665

704

766

854

1,064

1,338

1,666

2,144

2,592

3,024

3,659

- -

6.83

- -

11.91

10.27

8.75

9.16

10.27

8.86

5.58

10.12

8.70

8.79

9.89

8.81

7.94

- -

54.32

- -

76.43

44.21

32.44

24.59

20.24

14.84

9.32

17.30

14.79

16.84

13.06

12.29

12.13

- -

174.33

54.14

136.32

155.86

80.36

48.65

40.27

28.58